

▪ TALK ABSTRACT

ZECARDIO: A versatile screening platform for cardiovascular functional genomics and drug discovery

- Introduction of ZeCardio, a technology based in the use of zebrafish larvae for addressing cardiovascular physiology in vivo.
- Description of ZeCardio applications: Target validation and efficacy screenings.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 755988.

▪ SPEAKER BIO

Javier Terriente

Chief Scientific Officer and Co-Founder

ZeClinics, PRBB, Barcelona, Spain

Javier.terriente@zeclinics.com

Javier is Chief Scientific Officer (CSO) and co-founder at ZeClinics. He co-founded the company in 2013 and assumed full-term responsibilities from 2016.

As ZeClinics CSO, he is in charge of supervising every scientific aspect of ZeClinics activity: bringing new ideas, developing new products, assessing the quality of services and drug discovery platforms, asking for public and private funding, coordinating research projects, helping the commercial area in designing scientific proposals and searching for new clients and managing a growing and talented scientific team.

Before founding Zeclinics, Javier was an academic researcher in the field of developmental neurobiology. He did his PhD in the CBM-SO at Madrid (Spain) followed by two postdoctoral stays at NIMR-MRC in London (UK) and at DCEXS/UPF in Barcelona (Spain). In overall, he has 15 years of experience

across different academic institutions and 4 years in the pharmaceutical industry.

He is an expert in zebrafish biology and the exploitation of this animal model for functional genomic and drug discovery purposes. During his career, he has authored 18 articles and being granted different fellowships and research grants, including an H2020-SME Ph2.